What is Diklofenak retard Jugoremedija?
Diklofenak retard Jugoremedija is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and other symptoms of arthritis of the joints (eg, osteoarthritis), such as inflammation, swelling, stiffness, and joint pain. However, Diklofenak retard Jugoremedija does not cure osteoarthritis and will help you only as long as you continue to use it.
Diklofenak retard Jugoremedija topical 3% gel is also used to treat actinic keratosis, a skin problem that may become cancerous if not treated. The exact way that topical Diklofenak retard Jugoremedija helps this condition is unknown.
Diklofenak retard Jugoremedija topical solution is used to treat pain and swelling caused by osteoarthritis of the knees.
Diklofenak retard Jugoremedija topical patch is used to treat acute pain caused by minor strains, sprains, and contusions (bruises).
Diklofenak retard Jugoremedija is available only with your doctor's prescription.
Diklofenak retard Jugoremedija indications
Intramuscular
Renal colic
Adult: As Diklofenak retard Jugoremedija Na: 75 mg, may repeat once after 30 min if needed. Max: 150 mg/day. Max period: 2 days.
Intramuscular
Bursitis, Pain and inflammation associated with musculoskeletal and joint disorders, Rheumatoid arthritis, Sprains, Strains, Tendinitis, Acute gout, Dysmenorrhoea
Adult: As Diklofenak retard Jugoremedija Na: 75 mg once daily, injected into the gluteal muscle, may increase to 75 mg bid in severe conditions. Max period: 2 days.
Intravenous
Postoperative pain
Adult: As Diklofenak retard Jugoremedija Na: 75 mg infusion in glucose 5% or NaCl 0.9% (previously buffered w/ Na bicarbonate) given over 30-120 min or as bolus inj, may repeat after 4-6 hr if necessary. Max period: 2 days.
Intravenous
Prophylaxis of postoperative pain
Adult: As Diklofenak retard Jugoremedija Na: Initially, 25-50 mg infusion given after surgery over 15-60 min followed by 5 mg/hr. Alternatively, initial dose may be given as bolus inj over 5-60 sec followed by additional inj, may repeat after 4-6 hr if necessary. Max: 150 mg/day. Max period: 2 days.
Ophthalmic
Postoperative ocular inflammation
Adult: As Diklofenak retard Jugoremedija Na (0.1% soln): Instill into the appropriate eye 4 times daily starting 24 hr after surgery for up to 28 days.
Ophthalmic
Inflammation and discomfort after strabismus surgery
Adult: As Diklofenak retard Jugoremedija Na (0.1% soln): Instill 1 drop 4 times daily for the 1st wk; then tid in the 2nd wk, bid in the 3rd wk, and as required for the 4th wk.
Ophthalmic
Pain and discomfort after radial keratotomy
Adult: As Diklofenak retard Jugoremedija Na (0.1% soln): Instill 1 drop before surgery followed by 1 drop immediately after surgery, and then 1 drop 4 times daily for up to 2 days.
Ophthalmic
Pain after accidental trauma
Adult: As Diklofenak retard Jugoremedija Na (0.1% soln): Instill 1 drop 4 times daily for up to 2 days.
Ophthalmic
Control of inflammation after argon laser trabeculoplasty
Adult: As Diklofenak retard Jugoremedija Na (0.1% soln): Instill 1 drop 4 times during the 2 hr before procedure followed by 1 drop 4 times daily, up to 7 days after procedure.
Ophthalmic
Prophylaxis of intra-operative miosis
Adult: As Diklofenak retard Jugoremedija Na (0.1% soln): Instill into appropriate eye 4 times w/in 2 hr before surgery.
Ophthalmic
Post-photorefractive keratectomy pain
Adult: As Diklofenak retard Jugoremedija Na (0.1% soln): Instill into the affected eye twice, an hr before surgery, then 1 drop twice at 5-min intervals immediately after surgery, then every 2-5 hr while awake for up to 24 hr.
Ophthalmic
Seasonal allergic conjunctivitis
Adult: As Diklofenak retard Jugoremedija Na (0.1% soln): Instill 1 drop before surgery followed by 1 drop immediately after surgery, and then 1 drop 4 times daily for up to 2 days.
Oral
Bursitis, Pain and inflammation associated with musculoskeletal and joint disorders, Rheumatoid arthritis, Sprains, Strains, Tendinitis, Acute gout, Dysmenorrhoea
Adult: As Diklofenak retard Jugoremedija Na: 75-150 mg/day in divided doses. Max: 150 mg/day.
Oral
Migraine
Adult: As Diklofenak retard Jugoremedija K: Initially, 50 mg taken at the 1st sign of an attack, an additional dose of 50 mg may be taken after 2 hr if symptoms persist. If needed, further doses of 50 mg may be taken 4-6 hrly. Max: 200 mg/day.
Rectal
Acute gout, Bursitis, Dysmenorrhoea, Pain and inflammation associated with musculoskeletal and joint disorders, Rheumatoid arthritis, Sprains, Strains, Tendinitis
Adult: As Diklofenak retard Jugoremedija Na: 100 mg once daily.
Topical/Cutaneous
Actinic keratoses
Adult: As Diklofenak retard Jugoremedija Na (3% gel): Apply bid for 60-90 days.
Topical/Cutaneous
Osteoarthritis
Adult: As Diklofenak retard Jugoremedija Na (1.6% soln): Apply in small amounts (20 or 40 drops) onto affected area 4 times daily. As Na: (1% gel): Apply to the affected area 4 times daily. Max: 32 g/day over the affected area.
Topical/Cutaneous
Local symptomatic relief of pain and inflammation
Adult: As Diklofenak retard Jugoremedija Na (1% gel): Apply onto affected area 3 or 4 times daily.
Transdermal
Acute pain
Adult: Sprains, strains, contusions: 1 patch bid.
How should I use Diklofenak retard Jugoremedija?
Use Diklofenak retard Jugoremedija solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Diklofenak retard Jugoremedija solution comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Diklofenak retard Jugoremedija solution refilled.
- Do not apply Diklofenak retard Jugoremedija solution to infected skin; open wounds; or red, swollen, or peeling skin.
- Wash your hands immediately before and after using Diklofenak retard Jugoremedija solution.
- Wash the affected area and dry completely before using Diklofenak retard Jugoremedija solution.
- To apply Diklofenak retard Jugoremedija solution, dispense 10 drops at a time onto the knee or into your hand. Spread Diklofenak retard Jugoremedija solution evenly around the front, back, and sides of the knee. Repeat until you have used the whole dose.
- Be sure that you cover your entire knee with your dose of Diklofenak retard Jugoremedija solution. Do not use more than the recommended amount.
- Do not apply sunscreens, cosmetics, insect repellants, other topical medicines, or any other substance to the treated area until it is completely dry.
- Do not put on clothes over the treated area until it is completely dry.
- Do not wrap, bandage, or apply heat to the treated area.
- Let the treated skin dry before touching it or letting it touch anyone else's skin.
- Do not shower, bathe, or wash the treated area for at least 30 minutes after you use Diklofenak retard Jugoremedija solution.
- If you miss a dose of Diklofenak retard Jugoremedija solution, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Diklofenak retard Jugoremedija solution.
Uses of Diklofenak retard Jugoremedija in details
Diklofenak retard Jugoremedija is used to relieve pain from various conditions. This form of Diklofenak retard Jugoremedija is used to treat migraine headaches. Diklofenak retard Jugoremedija is a nonsteroidal anti-inflammatory drug (NSAID). It works by blocking your body's production of certain natural substances that cause inflammation. This effect helps to decrease swelling, pain, or fever.
OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.
This medication may also be used to treat gout attacks.
How to use Diklofenak retard Jugoremedija
Read the Medication Guide provided by your pharmacist before you start taking Diklofenak retard Jugoremedija and each time you get a refill. If you have any questions, ask your doctor or pharmacist.
Take this medication by mouth as directed by your doctor. Empty the contents of one packet into a cup containing 1 to 2 ounces (30 to 60 milliliters) of water. Mix well and drink all of it right away. Do not mix with any liquid other than water. If stomach upset occurs while taking this medication, take it with food, milk, or an antacid. However, if you take this medication with a meal high in fat, it may not work as well.
There are different brands and forms of this medication available. Because different forms do not have the same effects at equal strengths, do not switch forms of Diklofenak retard Jugoremedija unless your doctor tells you to.
To reduce your risk of stomach bleeding and other side effects, take this medication at the lowest effective dose. Do not increase your dose or take it more often than prescribed.
Pain medications work best if they are used as the first signs of pain occur. If you wait until the pain has worsened, the medication may not work as well.
Tell your doctor if your condition persists or worsens.
Diklofenak retard Jugoremedija description
The active substance is sodium-[o[(2,6-dichlorophenyl)-amino]-phenyl]-acetate (= Diklofenak retard Jugoremedija sodium).
Each enteric tablet contains 25 mg or 50 mg of Diklofenak retard Jugoremedija sodium.
One prolonged-release tablet contains 100 mg of Diklofenak retard Jugoremedija sodium.
Excipients/Inactive Ingredients: Gastro-Resistant Tablet: Core for 25 mg and 50 mg: Cellulose microcrystalline; lactose monohydrate; magnesium stearate; maize starch; povidone; silica, colloidal anhydrous; sodium starch glycolate (type A).
Coating for 25 mg and 50 mg: Hypromellose; iron oxide yellow (E172); macrogoglycerol hydroxystearate; methacrylic acid-ethyl acrylate copolymer; macrogol 8000; talc; titanium dioxide (E171); simeticone; alpha-octadecyl-omega-hydroxy-polyglykolether; sorbic acid.
Coating for 50 mg: Iron oxide red (E172).
SR Tablet: Tablet Core: Cetyl alcohol; magnesium stearate; povidone; silica; colloidal anhydrous; sucrose.
Tablet Coating: Hypromellose; iron oxide red (E172); macrogol 8000; polysorbate 80; sucrose; talc; titanium dioxide (E171). Printing Ink: Carbon black, shellac, ammonium hydroxide, simethicone.
Injection: Each ampoule also contains the following excipients: Mannitol, sodium metabisulfite (E223), benzyl alcohol, propylene glycol, water for injection, sodium hydroxide.
Diklofenak retard Jugoremedija dosage
General Dosing Instructions
Carefully consider the potential benefits and risks of Diklofenak retard Jugoremedija and other treatment options before deciding to use Diklofenak retard Jugoremedija. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.
The effectiveness of Diklofenak retard Jugoremedija when taken with food has not been studied in clinical studies. Taking Diklofenak retard Jugoremedija with food may cause a reduction in effectiveness compared to taking Diklofenak retard Jugoremedija on an empty stomach.
Acute Pain
For management of mild to moderate acute pain, the dosage is 18 mg or 35 mg orally three times daily.
Osteoarthritis Pain
For management of osteoarthritis pain, the dosage is 35 mg orally three times daily.
Dosage Adjustments in Patients with Hepatic Impairment
Patients with hepatic disease may require reduced doses of Diklofenak retard Jugoremedija compared to patients with normal hepatic function. As with other Diklofenak retard Jugoremedija products, start treatment at the lowest dose. If efficacy is not achieved with the lowest dose, discontinue use.
Non-Interchangeability with Other Formulations of Diklofenak retard Jugoremedija
Diklofenak retard Jugoremedija capsules are not interchangeable with other formulations of oral Diklofenak retard Jugoremedija even if the milligram strength is the same. Diklofenak retard Jugoremedija capsules contain Diklofenak retard Jugoremedija free acid whereas other Diklofenak retard Jugoremedija products contain a salt of Diklofenak retard Jugoremedija, i.e., Diklofenak retard Jugoremedija potassium or sodium. A 35 mg dose of Diklofenak retard Jugoremedija is approximately equal to 37.6 mg of sodium Diklofenak retard Jugoremedija or 39.5 mg of potassium Diklofenak retard Jugoremedija. Therefore, do not substitute similar dosing strengths of other Diklofenak retard Jugoremedija products without taking this into consideration.
Diklofenak retard Jugoremedija interactions
See also:
What other drugs will affect Diklofenak retard Jugoremedija?
Aspirin: Concomitant administration of Diklofenak retard Jugoremedija and aspirin is not recommended because Diklofenak retard Jugoremedija is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels and AUC values.
Anticoagulants: While studies have not shown Diklofenak retard Jugoremedija to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs. Because prostaglandins play an important role in hemostasis and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including Diklofenak retard Jugoremedija and warfarin, requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
Digoxin, Methotrexate, Cyclosporine: Diklofenak retard Jugoremedija, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs. Ingestion of Diklofenak retard Jugoremedija may increase serum concentrations of digoxin and methotrexate and increase cyclosporine's nephrotoxicity. Patients who begin taking Diklofenak retard Jugoremedija or who increase their Diklofenak retard Jugoremedija dose or any other NSAID while taking digoxin, methotrexate or cyclosporine may develop toxicity characteristics for these drugs. They should be observed closely, particularly if renal function is impaired. In the case of digoxin, serum levels should be monitored.
Lithium: Diklofenak retard Jugoremedija decreases lithium renal clearance and increases lithium plasma levels. In patients taking Diklofenak retard Jugoremedija and lithium concomitantly, lithium toxicity may develop.
Oral Hypoglycemics:
Diklofenak retard Jugoremedija does not alter glucose metabolism in normal subjects nor does it alter the effects of oral hypoglycemic agents. There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of Diklofenak retard Jugoremedija that necessitated changes in the doses of such agents. Both hypo- and hyperglycemic effects have been reported. A direct causal relationship has not been established, but physicians should consider the possibility that Diklofenak retard Jugoremedija may alter a diabetic patient's response to insulin or oral hypoglycemic agents.Diuretics: Diklofenak retard Jugoremedija and other NSAIDs can inhibit the activity of diuretics. Concomitant treatment with potassium-sparing diuretics may be associated with increased serum potassium levels.
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline or digitoxin did not significantly affect the peak levels and AUC values of Diklofenak retard Jugoremedija. Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of Diklofenak retard Jugoremedija therapy.
Diklofenak retard Jugoremedija side effects
See also:
What are the possible side effects of Diklofenak retard Jugoremedija?
There have been cases reported of Diklofenak retard Jugoremedija being associated with the development of symptoms resembling the syndrome of inappropriate antidiuretic hormone secretion in elderly women. A patient who had been taking Diklofenak retard Jugoremedija for several years and had increasingly complained of dry, gritty eyes noticed that eye irritation disappeared within 3 days when Diklofenak retard Jugoremedija had to be discontinued because of GI effects.
The most frequent adverse effects reported in patients given Diklofenak retard Jugoremedija are GI in nature. Typical reactions include epigastric pain, nausea, vomiting and diarrhoea. Rarely, peptic ulcer and GI bleeding have occurred. Diklofenak retard Jugoremedija has also been implicated as the causative agent in colonic ulceration, small bowel perforation and pseudomembranous colitis.
Renal papillary necrosis and nephritic syndrome have been reported in patients taking Diklofenak retard Jugoremedija. Elevations of serum aminotransferase activity and clinical hepatitis, including fetal fulminant hepatitis have occurred in patients taking Diklofenak retard Jugoremedija. Self-limiting skin reaction eg, rash or pruritus may occur in patients given Diklofenak retard Jugoremedija.
Aspirin-sensitive asthmatic patients have developed reactions (rhinorrhoea, tightness of chest, wheezing, dyspnoea) when challenged with Diklofenak retard Jugoremedija in doses of 10-25 mg and the CMS in the UK have received a report of 1 aspirin-sensitive patient who died from acute asthma 4 hrs after a single 25-mg dose of Diklofenak retard Jugoremedija.
Diklofenak retard Jugoremedija contraindications
See also:
What is the most important information I should know about Diklofenak retard Jugoremedija?
Hypersensitivity to Diklofenak retard Jugoremedija sodium or to any of the excipients of Diklofenak retard Jugoremedija.
Active gastric or intestinal ulcer, bleeding or perforation.
Last trimester of pregnancy.
Hepatic, renal and severe cardiac failure.
Patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by acetylsalicylic acid and/or other drugs with prostaglandin-synthetase inhibitory activity.
Treatment of peri-operative pain in setting of coronary artery bypass graft (CABG) surgery.
The use of high dose Diklofenak retard Jugoremedija (150 mg/day) for >4 weeks is contraindicated in patients with established cardiovascular disease (congestive heart failure, established ischemic heart disease, peripheral arterial disease) or uncontrolled hypertension.
Established Cardiovascular Disease or Significant Cardiovascular Risk Factors: The use of high dose Diklofenak retard Jugoremedija (150mg/day) for >4 weeks is contraindicated in patients with established cardiovascular disease (congestive heart failure, established ischemic heart disease, peripheral arterial disease) or uncontrolled hypertension. If Diklofenak retard Jugoremedija treatment is needed, patients with established cardiovascular disease, uncontrolled hypertension or significant cardiovascular risk factors (eg, hypertension, hyperlipidaemia, diabetes mellitus and smoking) should be treated only after careful consideration and at doses ≤100 mg daily if the treatment is for >4 weeks. As the cardiovascular risks of Diklofenak retard Jugoremedija may increase with dose and duration of exposure, Diklofenak retard Jugoremedija should always be prescribed at the lowest effective daily dose and for the shortest duration possible.
Renal Impairment: Diklofenak retard Jugoremedija is contraindicated in patients with renal failure. No specific studies have been carried out in patients with renal impairment, therefore, no specific dose adjustment recommendations can be made. Caution is advised when administering Diklofenak retard Jugoremedija to patients with mild to moderate renal impairment.
Hepatic Impairment: Diklofenak retard Jugoremedija is contraindicated in patients with hepatic failure. No specific studies have been carried out in patients with hepatic impairment, therefore, no specific dose adjustment recommendations can be made. Caution is advised when administering Diklofenak retard Jugoremedija to patients with mild to moderate hepatic impairment.
Active ingredient matches for Diklofenak retard Jugoremedija:
Diclofenac in Bosnia & Herzegowina.
List of Diklofenak retard Jugoremedija substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Diklofenak T Orifarm (Sweden) | |
| Diklofenako natrio (Lithuania) | |
| Diklofenako natrio 75mg Ilsanta (Lithuania) | |
| Dikloferol (Georgia, Latvia) | |
| Dikloferol N Aversi (Georgia) | |
| Dikloferol Olainfarm (Latvia) | |
| Diklojik (Turkey) | |
| Diklonat (Pakistan) | |
| Diklonat P (Bosnia & Herzegowina, Croatia (Hrvatska), Lithuania, Poland) | |
| Diklonat P 50 (Lithuania) | |
| Diklonat P retard (Lithuania) | |
| Diklonat P retard 100 (Lithuania) | |
| Diklopain (Turkey) | |
| Dikloron (Turkey) | |
| Dikloteva (Turkey) | |
| Dikmed (Poland) | |
| Dikol | |
| Dikol Diclofenac Sodium 25mg, BenzylAlcohol 0.9%w/v INJ / 25x3ml (New Gayzel Pharmaceuticals) | $ 3.01 |
| Dikol 75 mg Injection (New Gayzel Pharmaceuticals) | $ 0.04 |
| Dikol Diclofenac Sodium 25mg, BenzylAlcohol 0.9%w/v INJ / 25x3ml (New Gayzel Pharmaceuticals) | $ 3.01 |
| Dikonb (India) | |
| Dikonb 75mg x 3mL INJ / 3ml (N.B. Healthcare) | $ 0.10 |
| 75 mg x 3 mL x 3ml (N.B. Healthcare) | $ 0.10 |
| Dikonb 75 mg Injection (N.B. Healthcare) | $ 0.03 |
| DIKONB inj 75 mg x 3 mL x 3ml (N.B. Healthcare) | $ 0.10 |
| DIKPA INJ (India) | |
| DIKPA INJ inj 25 mg x 1 mL x 3ml (Keshav HC) | |
| Dikul (India) | |
| Dikul 75mg AMP / 3ml (Global Medisciences Limited (Intraways)) | $ 0.07 |
| Dikul 50mg TAB / 10 (Global Medisciences Limited (Intraways)) | $ 0.09 |
| 75 mg x 3ml (Global Medisciences Limited (Intraways)) | $ 0.07 |
| 50 mg x 10's (Global Medisciences Limited (Intraways)) | $ 0.09 |
| Dikul 75 mg Injection (Global Medisciences Limited (Intraways)) | $ 0.02 |
| Dikul 50 mg Tablet (Global Medisciences Limited (Intraways)) | $ 0.01 |
| DIKUL inj 75 mg x 3ml (Global Medisciences Limited (Intraways)) | |
| Dikul-SP (India) | |
| Dikul-SP Diclofenac potassium 50 mg, Serratiopeptidase 10 mg. TAB / 10 (Global MS (Intraways)) | $ 0.53 |
| 10's (Global MS (Intraways)) | $ 0.53 |
| DIKUL-SP tab 10's (Global MS (Intraways)) | $ 0.53 |
| Dikvol-GM (Georgia) | |
| Diky (Czech Republic, Poland, Slovakia) | |
| Diky 4% (Poland, Slovakia) | |
| Dilock (Bangladesh) | |
| Dilock-TR (Bangladesh) | |
| DILOFEN AQ | |
| DILOFEN AQ INJECTION 1 vial / 3 ML injection each (P & B Pharmaceuticals Ltd) | $ 0.90 |
| DILONA AQUA | |
| DILONA AQUA 75MG INJECTION 1 vial / 2 ML injection each (Mapra Laboratories Pvt Ltd) | $ 0.19 |
| Dilona D | |
| Dilona D 50 mg Tablet (Mapra Laboratories Pvt Ltd.) | $ 0.02 |
See 7738 substitutes for Diklofenak retard Jugoremedija | |
References
- DailyMed. "DICLOFENAC EPOLAMINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "diclofenac". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "diclofenac". http://www.drugbank.ca/drugs/DB00586 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Diklofenak retard Jugoremedija are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Diklofenak retard Jugoremedija. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
